跳至主要内容
临床试验/JPRN-UMIN000026927
JPRN-UMIN000026927已完成未知

A multicenter, prospective observational study of pegfilgrastim for the management of febrile neutropenia during ramucirumab plus docetaxel for patients with advanced non-small cell lung cancer (CJLSG 1602) - Observational study of pegfilgrastim for the management of febrile neutropenia during ramucirumab plus docetaxel

Central Japan Lung Study Group (CJLSG)0 个研究点目标入组 35 人开始时间: 2017年4月10日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
35

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
20years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1) Active infection 2) Patients had brain tumors and/or brain metastases (symptomatic or requiring treatment) 3) Evidence of tumor invading a perihilar blood vessel 4) Having a cavitating lung tumor 5) History of pulmonary hemorrhage or hemoptysis over 2.5 ml within 2 months 6) Evidence of tumor invading segmental bronchus 7) Severe gastrointestinal complications 8) Having a history or evidence of thrombosis 9) Severe hypertension 10) Having a history or evidence of ILD complication 11) Having an allergy of ramucirumab, docetaxel and pegfilgrastim 12) Having a severe mental disorder 13) Pregnant woman 14) Patients whose participation in the trial is judged to be inappropriate by the doctor

研究者

发起方
Central Japan Lung Study Group (CJLSG)

相似试验